Ok, you had me going. I read through the Ryan Costello article expecting to learn why restricting bad PBM behavior would constitute a windfall to Big Pharma. All I got was the disclaimer at the end that the author is a former member of Congress who is now a lobbyist. Patent reform should be a no-brainer, but Costello appears to be using it as a distraction.
Ok, you had me going. I read through the Ryan Costello article expecting to learn why restricting bad PBM behavior would constitute a windfall to Big Pharma. All I got was the disclaimer at the end that the author is a former member of Congress who is now a lobbyist. Patent reform should be a no-brainer, but Costello appears to be using it as a distraction.